THE WIRE · № 66744
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
01 THE MACHINE READ
WHY IT MATTERS.
Conference presentation on personalized cancer therapy keeps a small biotech's pipeline in view but adds no data.
Presentation-only update, no efficacy data disclosed
Future clinical trial results or regulatory news
No data means no real catalyst for shares
FULL DISPATCH
BETHESDA, Md., Oct. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Report of Possible $5 Billion Takeover Bid Sends Option Care Health Stock Higher2026-10-05 21:16 UTC
New Study Suggests Potential of penKid in Kidney Reserve Assessment2026-10-06 08:22 UTC
In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO2026-10-05 19:31 UTC
Pharma firms closed biopharma buyouts worth over a hundred billion dollars in the first half of the year, racing to replace top selling medicines worth around $400 billion before patents expire. Leah Bennett of Concurrent explains2026-10-05 20:15 UTC
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations2026-10-05 20:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.